Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review202
Systemic therapy for older patients with early breast cancer193
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in192
Editorial Board177
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis128
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty115
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer108
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group108
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)95
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas93
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer91
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives81
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis80
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer73
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials72
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines70
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.68
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches64
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features60
Editorial Board60
Emerging antibody-based therapies for the treatment of acute myeloid leukemia59
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis59
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?59
If it’s a target, it’s a pan-cancer target: Tissue is not the issue58
Optimizing care in early phase cancer trials: The role of palliative care55
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis53
Uncertainties and controversies in axillary management of patients with breast cancer53
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma53
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies52
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC52
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment51
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials50
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges50
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes46
Editorial Board46
Roadmap to cure multiple myeloma45
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck45
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?44
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review43
Editorial Board42
The immunogram of inflammatory breast cancer42
Overview of BH3 mimetics in ovarian cancer41
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis40
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination40
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside40
Editorial Board40
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier40
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada40
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design40
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review40
Extracellular vesicles and the “six Rs” in radiotherapy40
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)39
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis38
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma37
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma37
De-escalation of axillary irradiation for early breast cancer – Has the time come?37
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities35
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives35
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features35
Editorial Board34
Agnostic drug development revisited34
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer33
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies33
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer33
Malignant ascites: Current therapy options and treatment prospects33
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review33
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer33
Systematic review of the CUP trials characteristics and perspectives for next-generation studies32
Bone complications of cancer treatment32
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)32
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?31
Editorial Board31
Acknowledgement to Reviewers 202131
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis31
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers31
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer30
Editorial Board30
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?29
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review29
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review28
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review27
Local control strategies for management of NSCLC with oligoprogressive disease27
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review26
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications26
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges26
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification26
Cabozantinib: An evolving therapy for hepatocellular carcinoma26
Engineering strategies to optimise adoptive cell therapy in ovarian cancer25
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis25
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence25
Corrigendum to “Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis” [Cancer Treatm. Rev. 93 (2021) 102141]24
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives24
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives23
Review: Targeting EZH2 in neuroblastoma23
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]23
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond23
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review23
Strategies for improving detection of circulating tumor DNA using next generation sequencing22
Evolving immunotherapeutic solutions for triple-negative breast carcinoma22
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis22
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis22
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer22
Pharmacotherapy for leptomeningeal disease in breast cancer22
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project22
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications21
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment21
Editorial Board21
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases21
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review21
Editorial Board21
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature20
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review20
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors20
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives20
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis20
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies20
Editorial Board19
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]19
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives19
Editorial Board19
SELNET clinical practice guidelines for soft tissue sarcoma and GIST19
From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia19
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy19
Editorial Board19
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma19
Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma19
0.31428980827332